Publication

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

Paik, P. K., Felip, E., Veillon, R., Sakai, H., Cortot, A. B., Garassino, M. C., Mazieres, J., Viteri, S., Senellart, H., Van Meerbeeck, J., Raskin, J., Reinmuth, N., Conte, P., Kowalski, D., Cho, B. C., Patel, J. D., Horn, L., Griesinger, F., Han, J-Y., Kim, Y-C., Chang, G-C., Tsai, C-L., Yang, J. C-H., Chen, Y-M., Smit, E. F., van der Wekken, A. J., Kato, T., Juraeva, D., Stroh, C., Bruns, R., Straub, J., Johne, A., Scheele, J., Heymach, J. V. & Le, X., 29-May-2020, In : New England Journal of Medicine. 383, 10, p. 931-943 13 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

    Final publisher's version, 663 KB, PDF document

    Request copy

DOI

  • Paul K. Paik
  • Enriqueta Felip
  • Remi Veillon
  • Hiroshi Sakai
  • Alexis B. Cortot
  • Marina C. Garassino
  • Julien Mazieres
  • Santiago Viteri
  • Helene Senellart
  • Jan Van Meerbeeck
  • Jo Raskin
  • Niels Reinmuth
  • Pierfranco Conte
  • Dariusz Kowalski
  • Byoung Chul Cho
  • Jyoti D. Patel
  • Leora Horn
  • Frank Griesinger
  • Ji-Youn Han
  • Young-Chul Kim
  • Gee-Chen Chang
  • Chen-Liang Tsai
  • James C.-H. Yang
  • Yuh-Min Chen
  • Egbert F. Smit
  • Anthonie J. van der Wekken
  • Terufumi Kato
  • Dilafruz Juraeva
  • Christopher Stroh
  • Rolf Bruns
  • Josef Straub
  • Andreas Johne
  • Jürgen Scheele
  • John V. Heymach
  • Xiuning Le

BACKGROUND: A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population. METHODS: In this open-label, phase 2 study, we administered tepotinib (at a dose of 500 mg) once daily in patients with advanced or metastatic NSCLC with a confirmed MET exon 14 skipping mutation. The primary end point was the objective response by independent review among patients who had undergone at least 9 months of follow-up. The response was also analyzed according to whether the presence of a MET exon 14 skipping mutation was detected on liquid biopsy or tissue biopsy. RESULTS: As of January 1, 2020, a total of 152 patients had received tepotinib, and 99 patients had been followed for at least 9 months. The response rate by independent review was 46% (95% confidence interval [CI], 36 to 57), with a median duration of response of 11.1 months (95% CI, 7.2 to could not be estimated) in the combined-biopsy group. The response rate was 48% (95% CI, 36 to 61) among 66 patients in the liquid-biopsy group and 50% (95% CI, 37 to 63) among 60 patients in the tissue-biopsy group; 27 patients had positive results according to both methods. The investigator-assessed response rate was 56% (95% CI, 45 to 66) and was similar regardless of the previous therapy received for advanced or metastatic disease. Adverse events of grade 3 or higher that were considered by investigators to be related to tepotinib therapy were reported in 28% of the patients, including peripheral edema in 7%. Adverse events led to permanent discontinuation of tepotinib in 11% of the patients. A molecular response, as measured in circulating free DNA, was observed in 67% of the patients with matched liquid-biopsy samples at baseline and during treatment. CONCLUSIONS: Among patients with advanced NSCLC with a confirmed MET exon 14 skipping mutation, the use of tepotinib was associated with a partial response in approximately half the patients. Peripheral edema was the main toxic effect of grade 3 or higher. (Funded by Merck [Darmstadt, Germany]; VISION ClinicalTrials.gov number, NCT02864992.).

Original languageEnglish
Pages (from-to)931-943
Number of pages13
JournalNew England Journal of Medicine
Volume383
Issue number10
Publication statusPublished - 29-May-2020

ID: 126037259